Klin Monbl Augenheilkd 2024; 241(03): 302-307
DOI: 10.1055/a-2066-3389
Übersicht/Review

Neuroprotective Effects of Anti-diabetic Drugs in the Treatment of Patients with Diabetes and Glaucoma or at High Risk for Glaucoma

Artikel in mehreren Sprachen: deutsch | English
Burkhard Weisser
1   Sportmedizin, Institut für Sportwissenschaft, Kiel, Deutschland
,
2   Augenklinik am Wittenbergplatz, Berlin, Deutschland
› Institutsangaben

Abstract

There is an association between glaucoma and several risk factors and metabolic diseases, such as type 2 diabetes mellitus. Diabetes mellitus leads to neurodegenerative changes, both peripherally and in the brain. This might be a shared pathophysiology and etiology for both glaucoma and diabetes. It is interesting that drugs for the treatment of diabetes seem to have neuroprotective properties independent of their blood sugar reduction. Although prospective, randomized, clinical studies are still missing, particularly metformin and glucagon-like peptide receptor agonists (GLP 1 RA) seem to have neuroprotective effects. Sulphonylureas (e.g., glibenclamide, glimepiride) are still used. They frequently potently reduce blood pressure but may be less neuroprotective. In the present review, the evidence for neuroprotective effects of the different antidiabetic drugs is presented and a possible differential therapy for patients with diabetes and glaucoma, or at high risk of glaucoma, will be discussed.



Publikationsverlauf

Eingereicht: 16. Dezember 2022

Angenommen: 29. März 2023

Artikel online veröffentlicht:
19. Juni 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany